Viatris completed the divestiture of its OTC Business, API business in India, and women's healthcare business. These divestitures are part of a strategy to simplify and streamline the business, accelerate debt paydown, and unlock value.

The Company acquired exclusive global development and commercialization rights to two Phase 3 assets from Idorsia, including selatogrel and cenerimod, to expand its innovative portfolio and address unmet medical needs.

The document states "We expect R&D expense to increase in excess of $100 million in 2025 as compared to 2024 primarily as a result of increased expenses for the selatogrel and cenerimod development programs."

Following an inspection by the FDA at its oral finished dose manufacturing facility in Indore, India, the FDA has issued a warning letter and an import alert related to this facility, impacting the ability to distribute certain products into the U.S.

The Company currently estimates the negative impact to 2025 total revenues to be approximately $500 million and to 2025 earnings from operations to be approximately $385 million due to the FDA warning letter and import alert related to the Indore facility.

The Company immediately implemented a comprehensive remediation plan at the site, engaging independent third-party subject matter experts to support the remediation plan and is in regular communication with the FDA.

The 10-K states, "There are ongoing risks and uncertainties associated with our recent divestitures, one or more of which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, and/or stock price."

The 10-K states, "We have and may continue to experience pressure on the pricing of and reimbursements for certain of our products due to pricing controls, social or government pressure to lower the cost of drugs, and consolidation across the supply chain."

The 10-K states, "We have significant operations globally, which exposes us to the risks inherent in conducting our business internationally." These risks include compliance with local laws, less established legal regimes, and potential for governmental favoritism.

The 10-K states, "The pharmaceutical industry is highly competitive. We face competition from other pharmaceutical manufacturers globally, some of whom are significantly larger than us and have stronger, more well-established reputations than us."

The 10-K states, "We also face increasing competition from lower-cost generic products and other branded products. As we focus on developing or acquiring innovative, best-in-class, patent-protected assets, competition from manufacturers of generic or biosimilar drugs, including from generic versions of competitors' branded products that lose their market exclusivity, has been and will continue to be a major challenge for our patent-protected and branded products."

The 10-K states, "Our future success is highly dependent on our ability to attract, motivate and retain key personnel."

The document states that the company is committed to maintaining the highest quality manufacturing standards at its facilities around the world and to continuous assessment and improvement in a time of evolving industry dynamics and regulatory expectations.

The document states that the company has designed its global operations and supply chain to be a reliable and flexible partner for access across the world, constantly adapting to an ever-evolving landscape.

The document states that the company is committed to advancing responsible and sustainable operations and work diligently to minimize our environmental footprint across the Viatris network while safeguarding access to medicine.

The document states that one of the Company's strategic pillars is our focus on expanding our innovative portfolio to identify, vet and secure best-in-class, patented-protected assets that address areas of significant unmet medical need.

The document states that Viatris invests a significant amount of capital and resources in R&D, and this amount is likely to increase as we focus on more complex and innovative products to drive accelerated and durable growth, and build a more durable higher margin portfolio with exclusivity opportunities.

The document states that the Company is also working with its partners on novel and/or complex products such as our biosimilar to BOTOX® (onabotulinumtoxinA).

The Company expects to continue to deliver on its long-term financial strategy to return capital to shareholders through dividends and share repurchases, while making investments in its business and maintaining its commitment to its investment grade debt rating.

The Board of Directors authorized a share repurchase program for the repurchase of up to $2.0 billion of the Company's shares of common stock.

The document states that one of the Company's strategic pillars is our focus on expanding our innovative portfolio to identify, vet and secure best-in-class, patented-protected assets that address areas of significant unmet medical need.

The document states that the Company is committed to making an impact in the communities it serves and to continue to be a model for sustainable access to medicine.

The document highlights Viatris' systematic efforts and progress across key areas including access and global health, workplace culture, and environment (climate, water, and waste).

The document states that Viatris' scope 1 & 2, and scope 3 emission reduction targets have been validated and approved by SBTi, and that SBTi classified Viatris' scope 1 & 2 targets as being aligned with the 1.5°C trajectory.

The 10-K states, "We operate in a complex and rapidly changing environment that involves risks, many of which are beyond our control."

The 10-K states, "Regulation by governmental authorities is a significant factor in the R&D, production, marketing, sales and distribution of pharmaceuticals."

The 10-K states, "The pharmaceutical industry is highly competitive. We face competition from other pharmaceutical manufacturers globally, some of whom are significantly larger than us and have stronger, more well-established reputations than us."